News & Updates

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

Use of spironolactone does not increase the risk of female breast cancer recurrence and may be considered for the treatment of alopecia in survivors, results of a recent study have shown.

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

Abrocitinib holds promise for moderate-to-severe AD

30 Sep 2020 by

The investigational JAK1* selective inhibitor abrocitinib was effective and well-tolerated in adolescents and adults with moderate-to-severe atopic dermatitis (AD), the phase III JADE MONO-2 trial has shown.

Abrocitinib holds promise for moderate-to-severe AD

30 Sep 2020

Relugolix mutes endometriosis pain

30 Sep 2020

Oral relugolix provides pain relief in women with endometriosis in a dose–response manner, according to the results of a phase II study.

Relugolix mutes endometriosis pain

30 Sep 2020

$Bisphosphonates pose risk of atypical femur fracture$

Bisphosphonates pose risk of atypical femur fracture

30 Sep 2020

Bisphosphonates bear an increased hazard of developing atypical femur fracture, which rapidly decreases following treatment discontinuation, according to a study. This risk is more pronounced in Asians than in whites.

Bisphosphonates pose risk of atypical femur fracture

30 Sep 2020

Nidufexor lowers ALT, hepatic fat in patients with NASH

30 Sep 2020 by

Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.

Nidufexor lowers ALT, hepatic fat in patients with NASH

30 Sep 2020

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020 by

The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020

Standardized order set during LVP safely lowers amount of albumin dosing

29 Sep 2020

Using an order set to guide albumin dosing based on the amount of ascitic fluid removed during large volume paracentesis (LVP) substantially reduces the quantity of albumin given with no difference in adverse effects, results of a study have shown.

Standardized order set during LVP safely lowers amount of albumin dosing

29 Sep 2020

Liver cirrhosis: Repeat FIB-4 test predicts who’s at risk

29 Sep 2020 by

A repeat fibrosis-4 (FIB-4) test ably identifies individuals at greatest risk for liver cirrhosis in a new study.

Liver cirrhosis: Repeat FIB-4 test predicts who’s at risk

29 Sep 2020

Acetaminophen exerts no opioid-sparing effect

29 Sep 2020

Intravenous acetaminophen does not effectively reduce opioid consumption in patients who have undergone surgery, according to a study.

Acetaminophen exerts no opioid-sparing effect

29 Sep 2020

Omitting clopidogrel the better strategy post-TAVI

29 Sep 2020 by

The use of aspirin alone following TAVI* significantly reduced bleeding vs aspirin plus clopidogrel in the POPular TAVI study. This benefit came without increasing thromboembolic events, effectively positioning aspirin as the better antithrombotic strategy after TAVI.

Omitting clopidogrel the better strategy post-TAVI

29 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Spironolactone does not up risk of breast cancer recurrence

Spironolactone does not up risk of breast cancer recurrence

Abrocitinib holds promise for moderate-to-severe AD

Abrocitinib holds promise for moderate-to-severe AD

Relugolix mutes endometriosis pain

Relugolix mutes endometriosis pain

Bisphosphonates pose risk of atypical femur fracture

Bisphosphonates pose risk of atypical femur fracture

Nidufexor lowers ALT, hepatic fat in patients with NASH

Nidufexor lowers ALT, hepatic fat in patients with NASH

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

Standardized order set during LVP safely lowers amount of albumin dosing

Standardized order set during LVP safely lowers amount of albumin dosing

Liver cirrhosis: Repeat FIB-4 test predicts who’s at risk

Liver cirrhosis: Repeat FIB-4 test predicts who’s at risk

Acetaminophen exerts no opioid-sparing effect

Acetaminophen exerts no opioid-sparing effect

Omitting clopidogrel the better strategy post-TAVI

Omitting clopidogrel the better strategy post-TAVI